WVE Key Statistics, Chart & Performance
The current stock price of WVE is 7.67 USD. In the past month the price decreased by -7.14%. In the past year, price decreased by -49.21%.
WVE Latest News, Press Relases and Analysis
WVE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.22 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 499.88B | ||
| MRK | MERCK & CO. INC. | 11.88 | 261.34B | ||
| PFE | PFIZER INC | 8.03 | 146.18B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.51 | 100.25B | ||
| ZTS | ZOETIS INC | 20.14 | 56.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 23.23B | ||
| VTRS | VIATRIS INC | 4.57 | 12.40B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.28 | 11.58B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.68 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.53B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.52B |
Related stock screener links
About WVE
Company Profile
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Company Info
WAVE LIFE SCIENCES LTD
7 Straits View, #12-00, Marina One East Tower
Singapore 018936 SG
CEO: Paul B. Bolno
Employees: 287
Phone: 6562363388
WAVE LIFE SCIENCES LTD / WVE FAQ
What does WAVE LIFE SCIENCES LTD do?
Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 287 full-time employees The company went IPO on 2015-11-11. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
What is the stock price of WAVE LIFE SCIENCES LTD today?
The current stock price of WVE is 7.67 USD. The price increased by 3.23% in the last trading session.
What is the dividend status of WAVE LIFE SCIENCES LTD?
WVE does not pay a dividend.
What is the ChartMill rating of WAVE LIFE SCIENCES LTD stock?
WVE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is WVE stock listed?
WVE stock is listed on the Nasdaq exchange.
What is WAVE LIFE SCIENCES LTD worth?
WAVE LIFE SCIENCES LTD (WVE) has a market capitalization of 1.22B USD. This makes WVE a Small Cap stock.
What is the next earnings date for WVE stock?
WAVE LIFE SCIENCES LTD (WVE) will report earnings on 2026-03-02, after the market close.
WVE Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to WVE. When comparing the yearly performance of all stocks, WVE is a bad performer in the overall market: 91.05% of all stocks are doing better.
WVE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to WVE. The financial health of WVE is average, but there are quite some concerns on its profitability.
WVE Financial Highlights
Over the last trailing twelve months WVE reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 32.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.63% | ||
| ROE | -92.28% | ||
| Debt/Equity | 0 |
WVE Forecast & Estimates
20 analysts have analysed WVE and the average price target is 20.34 USD. This implies a price increase of 165.14% is expected in the next year compared to the current price of 7.67.
For the next year, analysts expect an EPS growth of -48.65% and a revenue growth -12.14% for WVE